[Oral administration of doxapram in preterm neonates with aminophylline-resistant idiopathic apnea crisis].
Doxapram is an analeptic capable of stimulating both central and periferal areas of the respiratory system. During the last few years, intravenous infusion of doxapram has been carried out, with success, for the treatment of idiopathic apnea in preterm infants otherwise unresponsive to methylxantine. Since doxapram has a tendency to precipitate into various solution containing amino acids and calcium gluconate, oral administration has been suggested. The Authors in this study have seen that in 18 preterm infants suffering from idiopathic apnea unresponsive to amynofillina, an oral administration of doxapram at 12 mg/kg/6h resulted in a complete recovery from apnea spells in 66.7% of cases, while 22.2% gave a partial positive response and only 11.1% a negative result. Furthermore the Authors would like to stress that doxapram showed a good tolerance level when administered orally. In fact, no side effects which were previously reported in other publications were presented in the infants studied.
Romeo
M G
MG
Cattedra di Neonatologia, Università di Catania, Italia.
Betta
P
P
Tina
L G
LG
Cilauro
S
S
Saporito
A
A
Distefano
G
G
D000284:Administration, Oral; D000628:Aminophylline / Q000494:pharmacology; D001049:Apnea / Q000188:drug therapy*; D001993:Bronchodilator Agents; D004305:Dose-Response Relationship, Drug; D004315:Doxapram / Q000008:administration & dosage*; D004351:Drug Resistance; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D008297:Male
D001993:Bronchodilator Agents; D000628:Aminophylline; D004315:Doxapram